Dr Monif is a neurologist at Melbourne Health and Alfred Health and post-doctoral research fellow (Monash University), where she heads the Neuroimmunology, Neuroinflammation and Neurological Diseases Laboratory. She is also an honorary research fellow at the Dept of Physiology (The University of Melbourne). She has completed her FRACP specialist training in Neurology (2017) and a fellowship in neuroimmunology (2018). Her physician training was completed at Royal Melbourne Hospital. Her PhD was in Neuroscience and Neuroinflammation (Department of Physiology, The University of Melbourne), and her current research focus is in neuroinflammatory brain diseases. She is supervising 6 PhD students, 1 masters and 2 honours candidates in various translational neuroimmunology programs.
Multiple Sclerosis – New horizons in MS therapy and the multi systemic considerations in a patient with MS
MS is a chronic neuroinflammatory condition with associated demyelination and neurodegeneration. The most common type of MS is relapsing-remitting (RRMS) where new symptoms occur in isolated attacks (relapses) which can lead to permanent neurological deficits. RRMS can progress to secondary progressive MS. MS generally affects those in their early 30s and 40s and therefore the lifelong burden of disease can be quite significant. Currently, there are 13 available MS therapies and each with a unique profile of effects and side effects. There are peri-operative, pulmonary, endocrine, urological, orthopaedic, oncological, obstetric and gynaecological, psychiatric, psychological, cutaneous and infectious disease considerations to address during the life course of a patient with MS. This lecture will highlight some of the above issues with the aim of improving multi-disciplinary care of a patient with MS.